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Background: Despite advances in the treatment of hepatocellular carcinoma (HCC), a great proportion
of patients are eligible only for palliative therapy for reasons of advanced-stage disease or poor hepatic
reserve. The use of transarterial chemoembolization (TACE) in the palliation of non-resectable HCC has
shown a survival benefit in European and Asian populations. The aim of this study was to assess
the efficacy of TACE by analysing overall 5-year survival, interval changes of tumour size and serum
alpha-fetoprotein (AFP) levels in a prospective North American cohort.
Methods: From September 2005 to December 2010, 46 candidates for TACE were enrolled in the study.
Collectively, they underwent 102 TACE treatments. Data on tumour response, serum AFP and survival
were prospectively collected.
Results: In compensated cirrhotic patients, serial treatment with TACE had a stabilizing effect on tumour
size and reduced serum AFP levels during the first 12 months. Overall survival rates at 1, 2 and 3 years
were 69%, 58% and 20%, respectively. Younger individuals and patients with a lower body mass index,
affected by early-stage HCC with involvement of a single lobe, had better survival in univariate analysis.
After adjustment for risk factors, early tumour stage (T1 and T2 vs. T3 and T4) at diagnosis was the only
statistically significant predictor for survival.
Conclusions: In compensated cirrhotic patients, TACE is an effective palliative intervention and HCC
stage at diagnosis seems to be the most important predictor of longterm outcomes.
Keywords
hepatocellular carcinoma, transarterial chemoembolization, TACE, survival, predictors, multivariate Cox
regression survival analysis, body mass index, MELD
Received 28 June 2011; accepted 6 November 2011
Correspondence
Michele Molinari, Department of Surgery, Queen Elizabeth II Health Sciences Center, Dalhousie
University, Room 6-254 Victoria Building, 1276 South Park Street, Halifax, NS B3H 2Y9, Canada.
Tel: + 1 902 473 7624. Fax: + 1 902 473 7639. E-mail: michele.molinari@cdha.nshealth.ca
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in the world and the third most frequent cause of cancer-
related mortality.1 Although HCC is more common in Asia and
Africa, its incidence in theWestern world is increasing.2 According
to the Surveillance and Epidemiology End Results (SEER) regis-
tries in the USA, the age-adjusted incidence of HCC increased
from 1.3 per 100 000 in 1978–1980 to 6.6 per 100 000 in 2002.3
Hepatic resection or liver transplantation are the only curative
interventions for HCC, but the vast majority of patients are not
surgical candidates for reasons of advanced tumour stage or
underlying liver disease. Therefore, palliative modalities such as
local ablation and transarterial chemoembolization (TACE) are
the only possible therapies.4
This paper was presented at the Asia Pacific Hepatopancreatobiliary
Association Congress, 27–30 September 2011, Melbourne, Vic.
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TACE can be performed in patients who are unable to undergo
surgery and in patients on waiting lists for liver transplants in
order to prevent disease progression.5–7 The process combines the
injection of antineoplastic agents with the selective obstruction of
arteries feeding the tumour. This results in tumour cell necrosis
with preservation of normal liver parenchyma reducing the risk
for liver failure.8 During the last decade, TACE has also found a
role as a neoadjuvant treatment in resectable patients,9 with a
partial response observed in 17.0–61.9%,10 although a complete
response is extremely rare.9
TACE had been used for many years to treat patients with HCC
worldwide, but controversy about its efficacy was not completely
resolved until two randomized controlled trials (RCTs) showed it
to have survival benefit compared with supportive therapy.11,12
The literature on predictors of longterm survival in patients
undergoing TACE for primary hepatic tumours in Western coun-
tries remains limited. Therefore, the objectives of this study were
to analyse overall survival and tumour response in patients under-
going sequential TACE treatments for non-resectable HCC in a
tertiary university hospital in North America and to explore
potential prognostic factors.
Materials and methods
Patient population
The study was approved by the local institutional ethics review
board (ERB) (Queen Elizabeth II Health Sciences Centre, Halifax,
NS, Canada). All patients diagnosed with non-resectable and
non-ablatable HCCwere potential candidates. Patients affected by
HCC were triaged to their therapeutic algorithm according to
Barcelona Clinic Liver Cancer (BCLC) staging criteria.13 Cases of
HCC were considered non-resectable when at least one of these
conditions was present: a severe comorbidity prohibiting the
administration of general anaesthesia; liver dysfunction, and/or
portal hypertension contraindicating parenchyma loss during
radical tumour resection. Ablation therapy was not considered
when the maximum diameter of the tumour was >5 cm, when the
tumour was in proximity to major vascular or biliary structures,
or if the patient was affected by multifocal disease. All participants
were recruited from hepatology, oncology and surgical clinics
and underwent serial TACE sessions at intervals of 3–4 months
even when radiological cross-sectional studies showed stable
disease or partial response, according to the study protocol
submitted to the ERB.
Study design
From September 2005 until December 2010, 46 consecutive
patients satisfied the inclusion criteria and underwent a total of
102 TACE sessions. All participants were presented at multidisci-
plinary rounds during which medical oncologists, hepatologists,
surgeons and interventional radiologists reached a consensus on
the best treatment strategy for each patient. Data on patients’
clinical characteristics and survival were recorded prospectively.
Patients included in this study were all adults affected by non-
resectable and non-ablatable HCC in the presence of compen-
sated liver function (Child–Pugh class A or B),14 with Eastern
Cooperative Oncology Group (ECOG) performance status of
0–2,15 and without radiological evidence of extrahepatic disease
according to the 2005 guidelines of the American Association for
the Study of Liver Diseases (AASLD).16
Patients were excluded if they were aged <18 years, were
affected by advanced liver dysfunction (Child–Pugh class C) or
renal impairment (defined as serum creatinine of >180 mmol/l),
were allergic to i.v. dye, were diagnosed with extrahepatic disease,
had main portal vein or main branch portal vein thrombosis,
demonstrated total serum bilirubin >30 mmol/l, or were affected
by neutropenia (neutrophil count 1000/ml) or thrombocy-
topenia (platelet count 50 000/ml).
Multifocal tumours were recorded if multiple lesions were
identified in several segments of the same hepatic lobe; bilobar
disease was recorded when both lobes were involved according to
the Brisbane terminology of liver anatomy.17
In the presence of bilobar disease, chemoembolization of the
lobe with the greatest tumour burden was performed first, fol-
lowed by treatment of the contralateral lobe after 3–4 months.
Physical examination, radiological abdominal studies with i.v.
contrast injection, chest radiographs and haematological and
blood chemistry tests were obtained as per the study protocol at
the time of diagnosis and then prior to all TACE procedures or
more often if necessary.
Transarterial chemoembolization procedures were performed
every 3–4 months by dedicated interventional radiologists unless
extrahepatic disease, liver decompensation or significant side-
effects occurred. Patients who had transient liver decompensation
or who developed systemic infection or bone marrow suppression
during the duration of this study were re-evaluated every 3–4
months and were considered as candidates for repeat TACE if they
satisfied the original inclusion criteria.
All data were prospectively collected and entered into a digital
database with secure access.
TACE procedures
All patients underwent TACE administered by dedicated inter-
ventional radiologists following standard protocols. Abdominal
contrast computerized tomography (CT) or magnetic resonance
imaging (MRI) studies were obtained in the 4 weeks prior to
each therapeutic intervention. Intravenous fluid hydration
and parenteral antibiotic prophylaxis with 1 g cefazolin (or 1 g
vancomycin in patients allergic to cephalosporin) and 500 mg
metronidazole (or 600 mg clindamycin in patients allergic to met-
ronidazole) were administered before arterial groin catheteriza-
tion. Post-TACE, all patients received 4–8 mg i.v. ondasentron to
prevent nausea or vomiting. Patients affected by viral hepatitis B
received lamivudine (100 mg/day orally) 1 week prior to and con-
tinuing after TACE to prevent hepatitis flare-ups. A selective 4- or
5-French catheter was used to cannulate the common femoral
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artery and visceral angiography was carried out to assess the arte-
rial blood supply to the liver and to confirm patency of the portal
vein. Depending on the size, location and arterial supply of the
tumour, the tip of the catheter was then advanced into the right or
left hepatic artery or superselectively when possible using micro-
catheters measuring 2.5–3.0-French [Renegade® (Boston Scien-
tific Corp., Natick, MA, USA) or Cantata® (Cook Medical, Inc.,
Bloomington, IN, USA)]. Chemoembolization of only one lobe of
the liver was carried out in each TACE session after mixing doxo-
rubicin hydrochloride (75 mg/m2 body surface area) with 10 ml
of lipiodol (ethiodized poppy seed oil; E-Z-EM Canada, Inc.,
Montreal, QC, Canada). Polyvinyl alcohol particles (Contour®
PVA; Boston Scientific Corp.) of 45–700 mm in size were then
injected if the chemoembolized artery territory did not show stag-
nant flow after the infusion of the chemotoxic agent mixed with
lipiodol. During 2009 and 2010, doxorubicin eluting beads of
100–700 mm in size were used to perform TACE in eight patients
affected by HCC who were randomized in an international mul-
ticentre controlled trial comparing chemoembolization delivered
using drug-eluting beads with conventional TACE.All the patients
who were treated with doxorubicin eluting beads satisfied the
initial inclusion criteria for this study and signed a separate
consent form after their recruitment. Before discharge, all patients
underwent baseline post-treatment CT without parenteral con-
trast injection to assess the distribution of lipiodol in the tumour
or, in patients treated with drug-eluting beads who did not require
the use of lipiodol, with i.v. dye injection to assess the vascularity
of neoplastic lesions.
Aims of the study
The primary aims of the study were to assess the overall survival of
the cohort and to establish whether the presence of bilobar disease
and tumour size (T-stage) were predicting factors for the overall
survival of patients undergoing serial TACE sessions for non-
resectable HCC. The secondary aims of the study were to assess
tumour response according to RECIST (response evaluation
criteria in solid tumours) criteria10 and interval changes in serum
alpha-fetoprotein (AFP) as a biological marker of response to
the therapy.
Diagnosis of primary hepatic tumours
HCC was diagnosed when one cross-sectional study (triphasic
contrast abdominal CT scan or MRI) was suggestive for HCC in
the presence of elevated serum AFP (100 ng/ml). Alternatively,
HCC was diagnosed when two contrast-enhanced cross-sectional
studies concurred with the identification of hypervascular
tumours with portal vein washout. When diagnosis was not
established by non-invasive modalities, a percutaneous liver
biopsy was obtained according to the guidelines of the AASLD.16
Tumour staging
The largest tumour nodule identified by contrast cross-sectional
imaging was sized for each patient at the time of diagnosis and
before each TACE by one of the primary investigators (KME) and
measured according to the RECIST criteria.10 All the measure-
ments were performed using an electronic scale in millimetres
provided by the software used by the radiology department
at our institution (IMPAX Web1000™; Agfa HealthCare Corp.,
Greenville, SC, USA). Tumour–node–metastasis (TNM) classifi-
cation [American Joint Committee on Cancer (AJCC), 7th edi-
tion]18 was used to stratify tumours according to their largest
diameter.
Survival
Overall survival was defined as the time interval between the date
of the first TACE and the date when patients expired or were
censored. Patients were censored if they were alive at the time of
the closure of this study, when they had undergone liver trans-
plantation, or if they were lost to follow-up. For the latest group,
the time of censoring was defined as the last date of documented
follow-up at our institution or by the patient’s general practitio-
ner. Missing data were minimized by contacting patients, their
families or their primary physicians by telephone or by letter. A
patient’s date of demise was confirmed by any of the following
criteria: death certificate; data from the prospective provincial
tumour registry, or contact with the patient’s primary doctor or
next of kin. Longterm data were available for 43 participants; three
subjects were lost to follow-up.
Follow-up investigations
All patients were evaluated with physical examinations, chest
radiographs and serial radiological cross-sectional studies (CT or
MRI) with parenteral contrast infusion in addition to haemato-
logical and biochemical tests including serum AFP every 3–4
months until death or liver transplantation.
Sample size calculation
This study was powered to detect a minimal hazard ratio of 2.5,
assuming that the median survival of patients with T4 or bilobar
HCC undergoing TACE was 6–8 months, with an accrual period
of 48 months and a minimum of 24 months follow-up for the
entire cohort of patients. A total of 40 subjects were needed for a
two-tailed study with an alpha level of 0.05 and a beta level of 0.8.
Statistical and survival analysis
Summary statistics were constructed for the baseline values, using
frequencies and proportions for categorical data, andmedians and
ranges (minimum–maximum values) for continuous variables.
Categorical outcomes were analysed using the chi-squared test or
Fisher’s exact test as appropriate. Continuous variables were com-
pared using Mann–Whitney or Kruskal–Wallis tests. All statistical
tests were two-tailed and a P-value of <0.05 was considered sig-
nificant. For time-to-event outcomes, the distributions of time to
the first event were compared using the log-rank test. The Kaplan–
Meier method was used to estimate the absolute risk for each
event in each group, and hazard ratios and 95% confidence inter-
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vals (CIs) were estimated using the Cox proportional hazard
model. To identify the baseline and clinical variables associated
with the overall survival time, multivariable analysis was per-
formed using the Cox proportional hazard model with a stepwise
selection procedure set at thresholds of 0.10 for inclusion and 0.05
for exclusion. All statistical analyses were performed using spss
Version 19.0 (SPSS, Inc., Chicago, IL, USA).
Results
Patient characteristics
Among all the participants, six patients (13%) underwent cadav-
eric liver transplants after at least one TACE session and were
censored at the time of surgery, six patients (13%) had at least one
previous ablation and were recruited after developing recurrent
disease not treatable with locoregional therapy, and none received
any chemotherapy agent other than doxorubicin delivered by
selective or superselective hepatic arterial catheterization.
Tables 1 and 2 outline the demographic and clinical character-
istics of the study population and variables related to tumour
location and stage, in addition to serum AFP and biochemical
variables used to measure Model of End-stage Liver Disease
(MELD) scores in order to stratify each patient’s hepatic function.
Tumour response
A disease-stabilizing effect on tumour diameter was observed after
initiation of the treatment protocol, along with a concomitant
reduction in serum AFP. The period of reduction in these two
variables persisted for almost 1 year, corresponding to TACE
treatment 4, when both tumour size and serum AFP increased,
although this increase did not reach statistical significance
(Figs 1 and 2).
Survival
Median survival in this cohort was 18.2 months (95% CI 12.0–
23.2). Overall survival probabilities at 1, 2 and 3 years were 69%,
58% and 20%, respectively (Fig. 3).
In univariate analysis, early tumour stage and involvement of
only one hepatic lobe were predictors for better survival. Other
variables that emerged as positive predictors were: younger age;
lower body mass index (BMI); involvement of only one segment
of the liver, and the presence of three or fewer tumours (Table 3).
Multivariate Cox proportional hazard regression analysis
revealed that none of these variables reached statistical signifi-
cance after adjusting for tumour stage at the time of diagnosis
(Table 4).
Discussion
One of the relative contraindications to TACE for patients with
HCC and who are not candidates for resection or ablation is the
presence of moderate to severe liver dysfunction. In North
America, this is a common event because the majority of patients
affected by HCC have cirrhosis caused by hepatitis C virus (HCV)
infection, alcohol or non-alcoholic steatohepatitis (NASH). In
these patients, treatment modalities are more likely to be dictated
by their liver function than by tumour stage. Quite often, clini-
cians managing cirrhotic patients with HCCmust make a difficult
decision on whether the treatment is worth the potential risk for
liver decompensation or, in the worst case scenario, irreversible
organ failure and premature death. Therefore, it is important to
validate the impact of TACE on overall survival in patients treated
in geographical areas in which the incidence of HCC is low and
cirrhosis is often present at diagnosis.
The body of literature on outcomes in Asian patients undergo-
ing treatment for HCC is much greater than that for patients
living in theWest, where risk factors and the degree of liver disease
differ from those in other geographical areas.11,19–21 Although arte-
rial embolization with or without the addition of chemotherapy
Table 1 Study population characteristics
Variable
Age, years, median (range) 51 (44–83)
Gender, male, n 41
Risk factors for primary hepatic tumour, n
Viral hepatitis C 17
Viral hepatitis B 2
Non-alcoholic steatohepatitis 4
Alcohol 16
Other 7
Body mass index, median (range) 27.3 (20.1–39.0)
Body surface area, m2, median (range) 1.91 (1.56–2.51)
Candidates for liver transplantation, n 21
Number of patients transplanted, n 6
Prior interventions for hepatic tumour, n
Radiofrequency ablation 6
Histological diagnosis, n 9
Radiological diagnosis, n 37
Total number of TACE procedures 102
Number of TACE procedures/patient,
median (range)
1.5 (1–6)
Number of tumours/patient, median (range) 1.0 (1–6)
Total number of TACE procedures, n
Left lobe 2
Right lobe 28
Both lobes 16
Follow-up, months, median (range) 17.1 (2–48)
Interval between TACE 1 and TACE 2, weeks,
median (range)
17 (9–40)
Interval between TACE 2 and TACE 3, weeks,
median (range)
22 (17–32)
Interval between TACE 3 and TACE 4, weeks,
median (range)
13 (12–14)
TACE, transarterial chemoembolization.
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has been used for several decades in Asia,22 only in 2002 did two
RCTs report a significant survival advantage in non-resectable
HCC treated by TACE in comparison with best supportive
care.11,12 Llovet et al.11 reported 2-year survival rates of 63% and
27% in patients undergoing TACE and patients receiving best
supportive care, and Lo et al.12 reported 3-year survival rates of
26% and 3%, respectively. The survival advantage of TACE was
also supported by a recent meta-analysis that confirmed the
benefit of chemoembolization in selected patients.23 Since then,
TACE has become the standard of care for this group of patients,
as suggested in practice guidelines endorsed by the AASLD first in
2005 and then in 2011.16,24
The current study validates the benefit of TACE in a cohort of
Western patients, all of whom had cirrhosis at the time of diag-
nosis of HCC and were at high risk for liver decompensation.
With strict application of the BCLC triaging algorithm, patients
were selected and treated according to the most recent AASLD
practice guidelines with sequential sessions of TACE. Stabilization
of the tumour burden and reduction of serumAFP were observed
during the first year post-initiation of the treatment protocol.
Although the interval changes over time in tumour diameter and
serum tumour marker did not achieve significance, the median
survival and survival probability observed were comparable with
the results reported by other investigators.25,26 Overall survival
in the cohort of patients enrolled at our centre is comparable
with the survival results reported in the two earlier RCTs11,12
and confirmed by other groups in both Asian and Western
countries.7,19,20,26
In the current cohort, patients tolerated TACE well and were
discharged from hospital after only 1 or 2 days during which they
were treated for hydration or for abdominal pain arising from
the glissonian inflammation caused by the embolization of the
tumour. The most common immediate side-effect after TACE was
the development of post-embolization syndrome, which occurred
in 50% of patients. Severe side-effects included the development
of a hepatic abscess (one patient) and transient liver decompen-
sation with ascites responsive to diuretics (five patients). These
findings were similar to previously reported data.19
Previous European and Asian studies have examined prog-
nostic factors associated with improved outcomes after TACE. A
reduction in serum AFP after the intervention,27 the number of
TACE procedures,20,28 low MELD score,7 the absence of diffuse
disease26,29 and small tumour size30 have been shown to correlate
with better survival. In the current study, univariate analysis
showed survival to be significantly better in younger individuals
and in patients with higher BMI, with early-stage tumours
and with single lobe involvement. However, in multivariate
analysis the only significant variable associated with improved
survival was the presence of early-stage tumours (T1 and T2 vs. T3
and T4).
Previous studies have shown that the introduction of screening
for HCC is cost-effective, represents the only method for the early
detection of HCC and subsequently increases the percentage of
patients able to undergo curative interventions.31–33 The findings
of this study would also suggest that the use of screening pro-
grammes could be beneficial even when patients are not candi-
dates for surgery because tumour size is a prognostic factor for
response to TACE and overall survival. As HCC screening has
become the standard of care for cirrhotic patients, approximately
60% of subjects in the current cohort were enrolled in a screening
or surveillance programme although their compliance was sub-
optimal. The remaining patients had been diagnosed with HCC
after presenting with symptoms or signs of liver decompensation.
This group of patients had more advanced tumours and none of
them fulfilled the Milan criteria for liver transplantation.34
One of the limitations of this study is the relatively small
number of patients and the fact that not all subjects were evalu-
Table 2 Tumour and laboratory variables at diagnosis
Tumour and laboratory variables at diagnosis
Tumour characteristics, n
Single tumour 25
Multiple tumours 21
Size of the largest tumour, cm, median (range) 4.4 (1–14)
Location of tumour, n
Left lobe 2
Right lobe 28
Bilobar 16
Radiological vascular tumour invasion, n
Present 5
Absent 41
TNM classification (AJCC, 7th Edition), n
T1 9
T2 15
T3 22
White blood cell count, ¥109/l, median (range) 5.9 (2.7–11.8)
Red blood cells, ¥10120/l, median (range) 4.0 (2.7–5.2)
Platelets, ¥109/l, median (range) 112 (49–462)
International normalized ratio, median (range) 1.1 (1.0–2.4)
Potassium, mmol/l, median (range) 4.1 (3.4–5.3)
Sodium, mmol/l, median (range) 136 (127–143)
Creatinine, mmol/l, median (range) 73.5 (55–153)
Total bilirubin, mmol/l, median (range) 18 (4–88)
Albumin, g/l, median (range) 33 (22–42)
MELD scorea, median (range) 7.5 (4–16)
Patients with MELD scores 10, n 14
Serum alpha-fetoprotein level, median (range) 123 (1–206 006)
Patients with serum AFP 100 ng/ml, n 24
aMELD scores at diagnosis were calculated without adjusting for extra
points for the presence of hepatocellular carcinoma.36
TNM, tumour–node–metastasis; AJCC, American Joint Committee
on Cancer; MELD, Model for End-stage Liver Disease; AFP,
alpha-fetoprotein.
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ated for histological proof of HCC. Therefore, there is the poten-
tial risk that some patients treated with TACE were not affected by
primary malignant lesions of the liver, but, rather, by benign con-
ditions such as adenomas, focal nodular hyperplasia, and regen-
erative or dysplastic nodules that have radiological features similar
to those of HCC. The risk for misdiagnosis was minimized by the
fact that our protocol applied the criteria suggested by the AASLD
for the diagnosis of HCC, for which liver biopsy is not always
necessary in the presence of confirming cross-sectional contrast-
enhanced radiological studies and elevation of serum tumour
marker levels.16
Another limitation is that, during 2009 and 2010, doxorubicin
eluting beads were used to perform TACE in eight patients who
were enrolled in an international multicentre RCT comparing
chemoembolization delivered by drug-eluting beads with conven-
tional TACE.35 Although these patients satisfied the same inclu-
sion criteria as the rest of the cohort, and received the same
amount of doxorubicin per square metre of body surface area,
their therapy deviated from conventional TACE. As drug-eluting
beads enhance selective tumour drug delivery,35 an internal
analysis of possible different outcomes in patients treated with
drug-eluting beads vs. conventional therapy would have been
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Table 3 Univariate analysis of survival predictors
Variable Median P-value
Estimate SE 95% CI
Age, years
<60 24.000 2.726 18.657–29.343 0.092
60 18.000 0.663 16.700–19.300
Gender
Female 32.000 11.429 9.600–54.400 0.393
Male 22.000 2.498 17.103–26.897
Body mass index
<30 18.000 3.350 11.434–24.566 0.015
>30 48.000 12.565 23.374–72.626
Tumour stage
T1 48.000 0.000 0.025
T2 26.000 10.241 5.928–46.072
T3 18.000 3.318 11.496–24.504
Multifocality
No 32.000 6.480 19.299–44.701 0.013
Yes 17.000 3.536 10.070–23.930
Vascular invasion by radiological characteristics
No 23.000 3.026 17.069–28.931 0.679
Yes 12.000 8.500 0.000–28.660
Presence of 3 tumours
No 32.000 7.433 17.431–46.569 0.047
Yes 18.000 4.629 8.927–27.073
Single lobe vs. bilobar disease
Single lobe disease 32.000 4.849 22.497–41.503 0.030
Bilobar 17.000 3.118 10.889–23.111
Model for End-stage Liver Disease (MELD) score 10
No 22.000 2.676 16.754–27.246 0.228
Yes 13.000 5.233 2.743–23.257
Serum alpha-fetoprotein (AFP) 100 mg/ml
No 24.000 8.039 8.243–39.757 0.250
Yes 22.000 3.262 15.607–28.393
SE, standard error; 95% CI, 95% confidence interval.
Table 4 Multivariate Cox survival regression analysis
Variable B SE Wald d.f. P-value Exp(B) 95.0% CI for Exp(B)a
Age (cut-off value: 60 years) -0.283 0.479 0.347 1 0.556 0.754 0.295–1.929
Body mass index (cut-off value: 30) -0.041 0.915 0.002 1 0.964 0.959 0.160–5.765
Number of tumours (cut-off value: 3) -11.176 238.273 0.002 1 0.963 0.000 0.000–1.800 (E202)
Presence of bilobar disease 4.649 124.401 0.001 1 0.970 104.495 0.000–2.390 (E107)
Largest tumour diameter (cut-off value: 5 cm) 0.880 0.654 1.808 1 0.179 2.410 0.669–8.688
Venous tumour invasion 6.104 213.578 0.001 1 0.970 447.535 0.000–2.810 (E184)
MELD score not adjusted for HCC (cut-off value: 10) -0.098 0.905 0.012 1 0.914 0.907 0.154–5.341
Serum AFP level (cut-off value: 100 ng/ml) -0.207 0.534 0.150 1 0.699 0.813 0.285–2.318
aExponential terms.
SE, standard error; 95% CI, 95% confidence interval; MELD, Model for End-stage Liver Disease; HCC, hepatocellular carcinoma;
AFP, alpha-fetoprotein.
168 HPB
HPB 2012, 14, 162–170 © 2012 International Hepato-Pancreato-Biliary Association
interesting, but was not feasible given the small number of
patients. Nevertheless, the results of a large multicentre study
(PRECISIONV) did not confirm survival differences between the
two modalities although patients treated with drug-eluting beads
tolerated the intervention better.35
One of the strengths of this study was its prospective design
and the low attrition rate in the cohort, in which follow-up
data were available for 93% of patients. In addition, the man-
agement of patients recruited in this study was based on well-
established staging and therapeutic algorithms such as the BCLC
staging criteria13 and clinical guidelines endorsed by the
AASLD.16,24 Therefore, the results should be generalizable to
other populations of cirrhotic patients with similar selection and
treatment protocols.
This study would suggest that even in compensated cirrhotic
patients and patients with advanced tumour stage, bilobar
involvement and obesity, TACE provides a survival benefit in
comparison with supportive care. In addition, when properly
selected, liver decompensation leading to severe side-effects or
death after TACE is very infrequent, even in cirrhotic patients,
in whom tumour stage at the time of diagnosis appears to be the
most significant prognostic factor for survival.
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